DeDora Capital Inc. Cuts Stake in Danaher Corporation (NYSE:DHR)

DeDora Capital Inc. trimmed its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 45.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,728 shares of the conglomerate's stock after selling 1,434 shares during the quarter. DeDora Capital Inc.'s holdings in Danaher were worth $354,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. FAS Wealth Partners Inc. increased its position in Danaher by 20.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock worth $2,203,000 after buying an additional 1,639 shares during the last quarter. Asahi Life Asset Management CO. LTD. acquired a new stake in shares of Danaher during the first quarter worth approximately $539,000. Horizon Financial Services LLC raised its position in shares of Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after acquiring an additional 8,160 shares during the last quarter. Vision Capital Management Inc. bought a new stake in Danaher in the 1st quarter valued at $461,000. Finally, Eos Management L.P. lifted its position in Danaher by 55.8% in the 1st quarter. Eos Management L.P. now owns 40,567 shares of the conglomerate's stock valued at $8,316,000 after acquiring an additional 14,537 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DHR has been the topic of several research analyst reports. Royal Bank Of Canada reissued an "outperform" rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. UBS Group reduced their price target on shares of Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Wells Fargo & Company lowered their target price on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 23rd. Barclays reaffirmed an "overweight" rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Tuesday, April 22nd. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $248.48.

Insider Activity at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president directly owned 15,179 shares of the company's stock, valued at $3,005,442. This trade represents a 51.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Down 0.8%

DHR stock traded down $1.47 during trading hours on Tuesday, reaching $186.61. 3,496,523 shares of the stock were exchanged, compared to its average volume of 3,534,081. The firm's 50-day moving average is $196.13 and its 200-day moving average is $204.86. The company has a market cap of $133.55 billion, a price-to-earnings ratio of 36.12, a PEG ratio of 2.67 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the previous year, the company posted $1.72 earnings per share. The business's revenue was up 3.4% on a year-over-year basis. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.69%. Danaher's dividend payout ratio is currently 24.85%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.